mitoxantrone has been researched along with Carcinoma, Anaplastic in 55 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous Phase II studies using the combination of mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) in the treatment of metastatic breast carcinoma have shown this regimen to be active and well tolerated." | 9.08 | Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial. ( Birch, R; Greco, FA; Hainsworth, JD; Hopkins, LG; Jolivet, J, 1997) |
| "These data are consistent with a lack of therapeutic activity of mitoxantrone when administered by hepatic arterial infusion for the treatment of hepatocellular carcinoma or metastatic colorectal cancer." | 9.07 | A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. ( Abbruzzese, J; Ajani, JA; Carrasco, CH; Charnsangavej, C; Jones, DV; Levin, B; Patt, YZ; Wallace, S, 1993) |
| "A phase II trial was performed to evaluate the efficacy and toxicity of a combination of ifosfamide (IFX) and mitoxantrone (MXN) as first-line chemotherapy for metastatic breast carcinoma." | 9.07 | Ifosfamide and mitoxantrone as first-line chemotherapy for metastatic breast cancer. ( Bianco, A; Cuevas, MA; Lacava, JA; Leone, BA; Machiavelli, M; Perez, JE; Rabinovich, MG; Rodriguez, R; Romero, A; Vallejo, CT, 1993) |
| "In June 1986 we initiated an intra-peritoneal (IP) mitoxantrone chemotherapy trial as consolidation treatment for ovarian carcinoma in CR or PR after induction therapy (surgery + CHAP combination chemotherapy)." | 9.07 | Intraperitoneal mitoxantrone as consolidation treatment for stage III ovarian carcinoma: a pilot study. ( Audhuy, B; Barats, JC; Bergerat, JP; Dellenbach, P; Dufour, P; Herbrecht, R; Maloisel, F; Renaud, R; Ritter, P; Wendling, C, 1991) |
| "Three hundred thirty-one women with metastatic breast cancer were randomized to receive combination chemotherapy with either cyclophosphamide, Novantrone (mitoxantrone; Lederle Laboratories, Wayne, NJ), and fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and fluorouracil (CAF)." | 9.06 | A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. ( Bennett, JM; Cartwright, K; Doroshow, JH; Dukart, G; Krementz, ET; Muss, HB; Reisman, A; Schoch, I; Wolff, S, 1988) |
| "A retrospective analysis of intraperitoneal mitoxantrone instillation therapy for malignant ascites in advanced breast and gynecologic pelvic cancers was performed to confirm the efficacy and safety of this therapy." | 8.82 | Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. ( Holtappels, M; Leder, G; Link, KH; Roitman, M; Runnebaum, I; Staib, L; Urbanzyk, H, 2003) |
| "In patients with advanced hepatocellular carcinoma (HCC), combination chemotherapy using 5- fluorouracil, cisplatin, and mitoxantrone (FMP) could achieve a response rate > 20%, but the beneficial effect was compromised by formidable adverse events." | 7.77 | Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma. ( Chen, HC; Hsu, CL; Hung, CF; Lin, CC; Pan, KT; Sung, CM; Tseng, JH; Yeh, CT, 2011) |
| " Intraperitoneal mitoxantrone was administered at a dosage of 20-30 mg/mq repeated every 28 days if ascites was still present." | 7.69 | Mitoxantrone in the treatment of recurrent ascites of pretreated ovarian carcinoma. ( Berardi, F; Catino, A; de Lena, M; Fioretto, A; Gargano, G; Lorusso, V, 1994) |
| "Eleven patients (pts) with advanced refractory breast carcinoma were treated with combination chemotherapy (Planovin) including mitoxantrone 10 mg/m2 on day 1, cisplatin 60 mg/m2 on days 1-2, methotrexate 200 mg/m2 on day 15, vincristine 2 mg on day 15, leucovorin 15 mg/m2 on days 15-16 every 3 weeks." | 7.68 | Intensive chemotherapy with cisplatin, mitoxantrone, methotrexate and vincristine in metastatic breast cancer. ( Gardin, G; Guido, T; Miglietta, L; Pronzato, P; Queirolo, P; Repetto, L; Rosso, R, 1991) |
| "Fifteen patients with breast cancer treated with mitoxantrone preoperatively from December 1986 to June 1983 were evaluated as to treatment validity and histological response." | 7.68 | [Clinical and histological study on breast cancer treated by preoperative mitoxantrone]. ( Meng, ZX, 1990) |
| "Twenty-five evaluable patients with advanced non-squamous carcinoma of the uterine cervix were treated with mitoxantrone 12 mg/m2 every three weeks." | 7.67 | Mitoxantrone in the treatment of advanced non-squamous carcinoma of the cervix (a phase II trial of the gynecologic oncology group). ( Bundy, BN; Homesley, HD; Muss, HB; Wilbanks, G, 1987) |
| "A human colon carcinoma cell line selected for a 21-fold resistance to mitoxantrone was cross-resistant to the anthracycline, doxorubicin, but not to the anthracene, bisantrene." | 7.67 | Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. ( Alberts, DS; Cress, AE; Dalton, WS; Trent, JM, 1988) |
| "A subline of human colon carcinoma cells (WiDr/R) resistant to the cytotoxic effects of mitoxantrone in vitro, was developed by continuous exposure to increasing concentrations of drug." | 7.67 | Development of resistance and characteristics of a human colon carcinoma subline resistant to mitoxantrone in vitro. ( Durr, FE; Lindh, D; Wallace, RE, 1987) |
| "The effect of temperature on the cytotoxicity of mitoxantrone (MX) was investigated by exposing human WIDR colon carcinoma cells to elevated temperatures in the presence of drug." | 7.67 | Effect of hyperthermia on the sensitivity of human colon carcinoma cells to mitoxantrone. ( Durr, FE; Lumanglas, AL; Ruszala-Mallon, VM; Silva, J; Wang, BS, 1987) |
| "Thirty-one patients with ovarian cancer who had failed chemotherapy were treated, 24 at the MTD." | 6.68 | A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma. ( Baldwin, P; Buckner, CD; Greco, FA; Hainsworth, JD; Lewis, M; Schwartzberg, L; Weaver, CH; West, WH; Wittlin, F; Zhen, B, 1997) |
| "Stages II-IV ovarian cancer in pathologic complete remission (pCR) at second-look surgery have a high relapse rate (50%) during the first 2 years." | 6.67 | Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. ( Audhuy, B; Barats, JC; Bergerat, JP; Dellenbach, P; Duclos, B; Dufour, P; Giron, C; Oberling, F; Renaud, R; Ritter, J, 1994) |
| "Mitoxantrone was well tolerated and produced an overall response rate comparable to that of other single-agent therapies used in the treatment of advanced head and neck cancer." | 6.67 | Multicenter phase II trial of mitoxantrone in patients with advanced nasopharyngeal carcinoma in Southeast Asia: an Asian-Oceanian Clinical Oncology Association Group study. ( Choi, P; Choy, D; Dugan, M; Lee, S; Leung, T; Ngai, A; Prasad, U; Sham, J; Shiu, W; Teo, P, 1993) |
| "i." | 5.28 | Hyperthermia enhances mitoxantrone cytotoxicity on human breast carcinoma and sarcoma xenografts in nude mice. ( Mella, O; Roszinski, S; Wagner, T; Weiss, C; Wiedemann, G, 1992) |
| "One hundred nine patients with nonmetastatic breast carcinoma, recruited between May 1995 and February 1997, were included in a protocol combining chemotherapy with mitoxantrone and cyclophosphamide, administered intravenously in 4 cycles of 21 days, and concomitant radiotherapy." | 5.09 | Concomitant chemoradiotherapy for patients with nonmetastatic breast carcinoma: side effects, quality of life, and organization. ( Bouscary, ML; Camerlo, J; Genre, D; Gravis, G; Macquart-Moulin, G; Maraninchi, D; Moatti, JP; Resbeut, M; Viens, P, 1999) |
| "Previous Phase II studies using the combination of mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) in the treatment of metastatic breast carcinoma have shown this regimen to be active and well tolerated." | 5.08 | Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial. ( Birch, R; Greco, FA; Hainsworth, JD; Hopkins, LG; Jolivet, J, 1997) |
| "In June 1986 we initiated an intra-peritoneal (IP) mitoxantrone chemotherapy trial as consolidation treatment for ovarian carcinoma in CR or PR after induction therapy (surgery + CHAP combination chemotherapy)." | 5.07 | Intraperitoneal mitoxantrone as consolidation treatment for stage III ovarian carcinoma: a pilot study. ( Audhuy, B; Barats, JC; Bergerat, JP; Dellenbach, P; Dufour, P; Herbrecht, R; Maloisel, F; Renaud, R; Ritter, P; Wendling, C, 1991) |
| "From April 1990 to April 1992, a comparative study was carried out in 46 patients with advanced breast cancer treated by CMxMF (Cyclophosphamide, mitoxantrone, methotrexate, 5-fluorouracil) and CAMF regimens (Cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil)." | 5.07 | [Comparison of the therapeutic effect of CMxMF and CAMF regimens in the management of advanced breast cancer patients]. ( Chen, JA, 1993) |
| "These data are consistent with a lack of therapeutic activity of mitoxantrone when administered by hepatic arterial infusion for the treatment of hepatocellular carcinoma or metastatic colorectal cancer." | 5.07 | A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. ( Abbruzzese, J; Ajani, JA; Carrasco, CH; Charnsangavej, C; Jones, DV; Levin, B; Patt, YZ; Wallace, S, 1993) |
| "A phase II trial was performed to evaluate the efficacy and toxicity of a combination of ifosfamide (IFX) and mitoxantrone (MXN) as first-line chemotherapy for metastatic breast carcinoma." | 5.07 | Ifosfamide and mitoxantrone as first-line chemotherapy for metastatic breast cancer. ( Bianco, A; Cuevas, MA; Lacava, JA; Leone, BA; Machiavelli, M; Perez, JE; Rabinovich, MG; Rodriguez, R; Romero, A; Vallejo, CT, 1993) |
| "Three hundred thirty-one women with metastatic breast cancer were randomized to receive combination chemotherapy with either cyclophosphamide, Novantrone (mitoxantrone; Lederle Laboratories, Wayne, NJ), and fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and fluorouracil (CAF)." | 5.06 | A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. ( Bennett, JM; Cartwright, K; Doroshow, JH; Dukart, G; Krementz, ET; Muss, HB; Reisman, A; Schoch, I; Wolff, S, 1988) |
| "A retrospective analysis of intraperitoneal mitoxantrone instillation therapy for malignant ascites in advanced breast and gynecologic pelvic cancers was performed to confirm the efficacy and safety of this therapy." | 4.82 | Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. ( Holtappels, M; Leder, G; Link, KH; Roitman, M; Runnebaum, I; Staib, L; Urbanzyk, H, 2003) |
| "In patients with advanced hepatocellular carcinoma (HCC), combination chemotherapy using 5- fluorouracil, cisplatin, and mitoxantrone (FMP) could achieve a response rate > 20%, but the beneficial effect was compromised by formidable adverse events." | 3.77 | Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma. ( Chen, HC; Hsu, CL; Hung, CF; Lin, CC; Pan, KT; Sung, CM; Tseng, JH; Yeh, CT, 2011) |
| "Twenty-eight women with primary operable breast carcinoma received 2M (mitoxantrone 11 mg/m2, methotrexate 35 mg/m2 every 3 weeks) for 4 cycles before surgery/radiotherapy, and an additional 2 cycles were given after surgery." | 3.70 | Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. ( Allred, DC; Ashley, SE; Chang, J; Dowsett, M; Ormerod, M; Powles, TJ, 2000) |
| "We selected a human colon carcinoma cell line in increasing concentrations of mitoxantrone to obtain a resistant subline, S1-M1-3." | 3.70 | Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. ( Annable, T; Brown, E; Collins, KI; Greenberger, LM; He, H; Rabindran, SK; Singh, M, 1998) |
| " Intraperitoneal mitoxantrone was administered at a dosage of 20-30 mg/mq repeated every 28 days if ascites was still present." | 3.69 | Mitoxantrone in the treatment of recurrent ascites of pretreated ovarian carcinoma. ( Berardi, F; Catino, A; de Lena, M; Fioretto, A; Gargano, G; Lorusso, V, 1994) |
| "Eleven patients (pts) with advanced refractory breast carcinoma were treated with combination chemotherapy (Planovin) including mitoxantrone 10 mg/m2 on day 1, cisplatin 60 mg/m2 on days 1-2, methotrexate 200 mg/m2 on day 15, vincristine 2 mg on day 15, leucovorin 15 mg/m2 on days 15-16 every 3 weeks." | 3.68 | Intensive chemotherapy with cisplatin, mitoxantrone, methotrexate and vincristine in metastatic breast cancer. ( Gardin, G; Guido, T; Miglietta, L; Pronzato, P; Queirolo, P; Repetto, L; Rosso, R, 1991) |
| "Fifteen patients with breast cancer treated with mitoxantrone preoperatively from December 1986 to June 1983 were evaluated as to treatment validity and histological response." | 3.68 | [Clinical and histological study on breast cancer treated by preoperative mitoxantrone]. ( Meng, ZX, 1990) |
| "To define both the toxicity and efficacy of intraperitoneal mitoxantrone in the treatment of refractory ovarian carcinoma, 31 patients were entered onto a phase II trial of this agent delivered in a 2 L treatment volume on a monthly basis." | 3.68 | Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. ( Almadrones, L; George, M; Hakes, T; Hoskins, W; Jones, W; Lewis, JL; Markman, M; Reichman, B; Rubin, S, 1990) |
| "From October 1985 to November 1987, arterial regional chemotherapy with mitoxantrone was undertaken in 18 patients with primary far advanced carcinoma of the breast, of inflammatory or ulcerating type." | 3.67 | [Arterial regional chemotherapy of advanced breast cancer]. ( de Dycker, RP; Neumann, RL; Schindler, AE; Timmermann, J; Wever, H, 1988) |
| "A human colon carcinoma cell line selected for a 21-fold resistance to mitoxantrone was cross-resistant to the anthracycline, doxorubicin, but not to the anthracene, bisantrene." | 3.67 | Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. ( Alberts, DS; Cress, AE; Dalton, WS; Trent, JM, 1988) |
| "The effect of temperature on the cytotoxicity of mitoxantrone (MX) was investigated by exposing human WIDR colon carcinoma cells to elevated temperatures in the presence of drug." | 3.67 | Effect of hyperthermia on the sensitivity of human colon carcinoma cells to mitoxantrone. ( Durr, FE; Lumanglas, AL; Ruszala-Mallon, VM; Silva, J; Wang, BS, 1987) |
| "Twenty-five evaluable patients with advanced non-squamous carcinoma of the uterine cervix were treated with mitoxantrone 12 mg/m2 every three weeks." | 3.67 | Mitoxantrone in the treatment of advanced non-squamous carcinoma of the cervix (a phase II trial of the gynecologic oncology group). ( Bundy, BN; Homesley, HD; Muss, HB; Wilbanks, G, 1987) |
| "A subline of human colon carcinoma cells (WiDr/R) resistant to the cytotoxic effects of mitoxantrone in vitro, was developed by continuous exposure to increasing concentrations of drug." | 3.67 | Development of resistance and characteristics of a human colon carcinoma subline resistant to mitoxantrone in vitro. ( Durr, FE; Lindh, D; Wallace, RE, 1987) |
| "Twenty-one chemotherapy naive ovarian cancer patients with stage III and minimal residual tumor were treated with cisplatin 75 mg/m2 and mitoxantrone 15 mg/m2 (1st day) by intraperitoneal (i." | 2.69 | Intraperitoneal cisplatin-mitoxantrone and intravenous ifosfamide combination as first-line treatment of ovarian cancer. ( Aydmer, A; Bengisu, E; Berkman, S; Saip, P; Salihoğlu, Y; Topuz, E, 1998) |
| "Thirty-one patients with ovarian cancer who had failed chemotherapy were treated, 24 at the MTD." | 2.68 | A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma. ( Baldwin, P; Buckner, CD; Greco, FA; Hainsworth, JD; Lewis, M; Schwartzberg, L; Weaver, CH; West, WH; Wittlin, F; Zhen, B, 1997) |
| "Stages II-IV ovarian cancer in pathologic complete remission (pCR) at second-look surgery have a high relapse rate (50%) during the first 2 years." | 2.67 | Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. ( Audhuy, B; Barats, JC; Bergerat, JP; Dellenbach, P; Duclos, B; Dufour, P; Giron, C; Oberling, F; Renaud, R; Ritter, J, 1994) |
| "Mitoxantrone was well tolerated and produced an overall response rate comparable to that of other single-agent therapies used in the treatment of advanced head and neck cancer." | 2.67 | Multicenter phase II trial of mitoxantrone in patients with advanced nasopharyngeal carcinoma in Southeast Asia: an Asian-Oceanian Clinical Oncology Association Group study. ( Choi, P; Choy, D; Dugan, M; Lee, S; Leung, T; Ngai, A; Prasad, U; Sham, J; Shiu, W; Teo, P, 1993) |
| "Patients with peritoneal carcinomatosis of various origin underwent surgery, including intestinal resections, with minimal residual disease." | 1.31 | Intraperitoneal mitoxantrone: a feasibility and pharmacokinetic study. ( Civalleri, D; De Cian, F; DeCian, F; Esposito, M; Lunardi, G; Pastrone, I; Steinweg, M; Vannozzi, MO; Viale, M, 2002) |
| "i." | 1.28 | Hyperthermia enhances mitoxantrone cytotoxicity on human breast carcinoma and sarcoma xenografts in nude mice. ( Mella, O; Roszinski, S; Wagner, T; Weiss, C; Wiedemann, G, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (18.18) | 18.7374 |
| 1990's | 31 (56.36) | 18.2507 |
| 2000's | 6 (10.91) | 29.6817 |
| 2010's | 7 (12.73) | 24.3611 |
| 2020's | 1 (1.82) | 2.80 |
| Authors | Studies |
|---|---|
| Clerc-Renaud, B | 1 |
| Gieger, TL | 1 |
| LaRue, SM | 1 |
| Nolan, MW | 1 |
| Schad, F | 1 |
| Atxner, J | 1 |
| Buchwald, D | 1 |
| Happe, A | 1 |
| Popp, S | 1 |
| Kröz, M | 1 |
| Matthes, H | 1 |
| Vignani, F | 1 |
| Bertaglia, V | 1 |
| Buttigliero, C | 1 |
| Tucci, M | 1 |
| Scagliotti, GV | 1 |
| Di Maio, M | 1 |
| Rashed, WM | 1 |
| Zekri, W | 1 |
| Awad, M | 1 |
| Taha, H | 1 |
| Abdalla, B | 1 |
| Alfaar, AS | 1 |
| Boudin, L | 1 |
| Chabannon, C | 1 |
| Sfumato, P | 1 |
| Sabatier, R | 1 |
| Bertucci, F | 1 |
| Tarpin, C | 1 |
| Provansal, M | 1 |
| Houvenaeghel, G | 1 |
| Lambaudie, E | 1 |
| Tallet, A | 1 |
| Resbeut, M | 2 |
| Charafe-Jauffret, E | 1 |
| Calmels, B | 1 |
| Lemarie, C | 1 |
| Boher, JM | 1 |
| Extra, JM | 1 |
| Viens, P | 2 |
| Gonçalves, A | 1 |
| Yeh, CT | 1 |
| Chen, HC | 1 |
| Sung, CM | 1 |
| Hsu, CL | 1 |
| Lin, CC | 1 |
| Pan, KT | 1 |
| Tseng, JH | 1 |
| Hung, CF | 1 |
| Fizazi, K | 1 |
| De Bono, JS | 1 |
| Flechon, A | 1 |
| Heidenreich, A | 1 |
| Voog, E | 1 |
| Davis, NB | 1 |
| Qi, M | 1 |
| Bandekar, R | 1 |
| Vermeulen, JT | 1 |
| Cornfeld, M | 1 |
| Hudes, GR | 1 |
| Spugnini, EP | 1 |
| Fanciulli, M | 1 |
| Citro, G | 1 |
| Baldi, A | 1 |
| Jaster, JH | 1 |
| Niell, HB | 1 |
| Dohan, FC | 1 |
| Smith, TW | 1 |
| Link, KH | 2 |
| Roitman, M | 1 |
| Holtappels, M | 1 |
| Runnebaum, I | 1 |
| Urbanzyk, H | 1 |
| Leder, G | 1 |
| Staib, L | 1 |
| Joss, RA | 1 |
| Cavalli, F | 1 |
| Goldhirsch, A | 1 |
| Mermillod, B | 1 |
| Brunner, KW | 1 |
| Leo, AD | 1 |
| Biganzoli, L | 1 |
| Bohm, S | 1 |
| Lupi, G | 1 |
| Oriana, S | 1 |
| Riboldi, G | 1 |
| Spatti, G | 1 |
| Vicario, G | 1 |
| Di Re, F | 1 |
| Bajetta, E | 1 |
| Philpott, NJ | 1 |
| Bevan, DH | 1 |
| Gordon-Smith, EC | 1 |
| Dufour, P | 2 |
| Bergerat, JP | 2 |
| Barats, JC | 2 |
| Giron, C | 1 |
| Duclos, B | 1 |
| Dellenbach, P | 2 |
| Ritter, J | 1 |
| Renaud, R | 2 |
| Audhuy, B | 2 |
| Oberling, F | 1 |
| Genne, P | 1 |
| Olsson, NO | 1 |
| Gutierrez, G | 1 |
| Duchamp, O | 1 |
| Chauffert, B | 1 |
| Lorusso, V | 1 |
| Catino, A | 1 |
| Gargano, G | 1 |
| Fioretto, A | 1 |
| Berardi, F | 1 |
| de Lena, M | 1 |
| Chen, JA | 1 |
| Calais, G | 1 |
| Descamps, P | 1 |
| Chapet, S | 1 |
| Turgeon, V | 1 |
| Reynaud-Bougnoux, A | 1 |
| Lemarié, E | 1 |
| Fignon, A | 1 |
| Body, G | 1 |
| Bougnoux, P | 1 |
| Lansac, J | 1 |
| Jones, DV | 1 |
| Patt, YZ | 1 |
| Ajani, JA | 1 |
| Abbruzzese, J | 1 |
| Carrasco, CH | 1 |
| Charnsangavej, C | 1 |
| Levin, B | 1 |
| Wallace, S | 1 |
| Tarraza, HM | 1 |
| Boyce, CR | 1 |
| Smith, WG | 1 |
| Jones, MA | 1 |
| Dugan, M | 1 |
| Choy, D | 1 |
| Ngai, A | 1 |
| Sham, J | 1 |
| Choi, P | 1 |
| Shiu, W | 1 |
| Leung, T | 1 |
| Teo, P | 1 |
| Prasad, U | 1 |
| Lee, S | 1 |
| Perez, JE | 1 |
| Machiavelli, M | 1 |
| Leone, BA | 1 |
| Romero, A | 1 |
| Rabinovich, MG | 1 |
| Vallejo, CT | 1 |
| Bianco, A | 1 |
| Lacava, JA | 1 |
| Rodriguez, R | 1 |
| Cuevas, MA | 1 |
| Fernando, IN | 1 |
| Ford, HT | 1 |
| Powles, TJ | 2 |
| Ashley, S | 2 |
| Glees, JP | 1 |
| Torr, M | 1 |
| Grafton, D | 1 |
| Harmer, CL | 1 |
| Hainsworth, JD | 2 |
| Jolivet, J | 1 |
| Birch, R | 1 |
| Hopkins, LG | 1 |
| Greco, FA | 2 |
| Barakat, RR | 1 |
| Fennelly, D | 1 |
| Pizzuto, F | 1 |
| Venkatraman, ES | 1 |
| Brown, C | 1 |
| Curtin, JP | 1 |
| Weaver, CH | 1 |
| Zhen, B | 1 |
| Baldwin, P | 1 |
| Wittlin, F | 1 |
| Lewis, M | 1 |
| West, WH | 1 |
| Schwartzberg, L | 1 |
| Buckner, CD | 1 |
| Topuz, E | 1 |
| Saip, P | 1 |
| Aydmer, A | 1 |
| Salihoğlu, Y | 1 |
| Berkman, S | 1 |
| Bengisu, E | 1 |
| Deliĭski, T | 1 |
| Baĭchev, G | 1 |
| Popovska, S | 1 |
| Penkova, R | 1 |
| Rabindran, SK | 1 |
| He, H | 1 |
| Singh, M | 1 |
| Brown, E | 1 |
| Collins, KI | 1 |
| Annable, T | 1 |
| Greenberger, LM | 1 |
| Macquart-Moulin, G | 1 |
| Genre, D | 1 |
| Bouscary, ML | 1 |
| Gravis, G | 1 |
| Camerlo, J | 1 |
| Maraninchi, D | 1 |
| Moatti, JP | 1 |
| Tasinato, R | 1 |
| Godina, M | 1 |
| Biral, M | 1 |
| Nicoletto, O | 1 |
| Griggio, L | 1 |
| Harper-Wynne, C | 1 |
| English, J | 1 |
| Meyer, L | 1 |
| Bower, M | 1 |
| Archer, C | 1 |
| Sinnett, HD | 1 |
| Lowdell, C | 1 |
| Coombes, RC | 1 |
| Leder, GH | 1 |
| Pillasch, J | 1 |
| Kornmann, M | 1 |
| Danenberg, PV | 1 |
| Chang, J | 1 |
| Ormerod, M | 1 |
| Allred, DC | 1 |
| Ashley, SE | 1 |
| Dowsett, M | 1 |
| Matsumoto, Y | 1 |
| Takano, H | 1 |
| Nagao, S | 1 |
| Fojo, T | 1 |
| Civalleri, D | 1 |
| Vannozzi, MO | 1 |
| De Cian, F | 1 |
| DeCian, F | 1 |
| Lunardi, G | 1 |
| Steinweg, M | 1 |
| Pastrone, I | 1 |
| Viale, M | 1 |
| Esposito, M | 1 |
| Wiedemann, G | 1 |
| Mella, O | 1 |
| Roszinski, S | 1 |
| Weiss, C | 1 |
| Wagner, T | 1 |
| Koc, Y | 1 |
| Kars, SA | 1 |
| Kansu, E | 1 |
| Tekuzman, G | 1 |
| Baltali, E | 1 |
| Firat, D | 1 |
| Queirolo, P | 1 |
| Repetto, L | 1 |
| Gardin, G | 1 |
| Miglietta, L | 1 |
| Guido, T | 1 |
| Pronzato, P | 1 |
| Rosso, R | 1 |
| Glaholm, J | 1 |
| Mort, C | 1 |
| Yarnold, JR | 1 |
| Schlumberger, M | 1 |
| Parmentier, C | 1 |
| Delisle, MJ | 1 |
| Couette, JE | 1 |
| Droz, JP | 1 |
| Sarrazin, D | 1 |
| Maloisel, F | 1 |
| Ritter, P | 1 |
| Herbrecht, R | 1 |
| Wendling, C | 1 |
| Ogilvie, GK | 1 |
| Obradovich, JE | 1 |
| Elmslie, RE | 1 |
| Vail, DM | 1 |
| Moore, AS | 1 |
| Straw, RC | 1 |
| Dickinson, K | 1 |
| Cooper, MF | 1 |
| Withrow, SJ | 1 |
| Kober, F | 1 |
| Heiss, A | 1 |
| Keminger, K | 1 |
| Depisch, D | 1 |
| Meng, ZX | 1 |
| Markman, M | 1 |
| George, M | 1 |
| Hakes, T | 1 |
| Reichman, B | 1 |
| Hoskins, W | 1 |
| Rubin, S | 1 |
| Jones, W | 1 |
| Almadrones, L | 1 |
| Lewis, JL | 1 |
| Matuszyk, J | 1 |
| Kuśnierczyk, H | 1 |
| Radzikowski, C | 1 |
| Dalton, WS | 1 |
| Cress, AE | 1 |
| Alberts, DS | 1 |
| Trent, JM | 1 |
| Bennett, JM | 1 |
| Muss, HB | 2 |
| Doroshow, JH | 1 |
| Wolff, S | 1 |
| Krementz, ET | 1 |
| Cartwright, K | 1 |
| Dukart, G | 1 |
| Reisman, A | 1 |
| Schoch, I | 1 |
| Dietel, M | 1 |
| Arps, H | 1 |
| Gerding, D | 1 |
| Trapp, M | 1 |
| Sieck, M | 1 |
| Niendorf, A | 1 |
| de Dycker, RP | 1 |
| Timmermann, J | 1 |
| Neumann, RL | 1 |
| Wever, H | 1 |
| Schindler, AE | 1 |
| Wallace, RE | 1 |
| Lindh, D | 1 |
| Durr, FE | 2 |
| Wang, BS | 1 |
| Lumanglas, AL | 1 |
| Silva, J | 1 |
| Ruszala-Mallon, VM | 1 |
| Bundy, BN | 1 |
| Homesley, HD | 1 |
| Wilbanks, G | 1 |
| Erlichman, C | 1 |
| Tannock, IF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study to Evaluate the Cosmetic Outcome of Using Pencil Beam Scanning Proton Therapy for Accelerated Partial Breast Irradiation in Early Stage Breast Cancer[NCT03940248] | Phase 2 | 0 participants (Actual) | Interventional | 2020-07-01 | Withdrawn (stopped due to Due to insurance non-payment, no subjects were enrolled.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for mitoxantrone and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Topics: Androstenes; Anilides; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neo | 2016 |
Preclinical models in electrochemotherapy: the role of veterinary patients.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 2012 |
Intraperitoneal chemotherapy with mitoxantrone in malignant ascites.
Topics: Adult; Aged; Aged, 80 and over; Ascites; Carcinoma; Chemotherapy, Adjuvant; Dose-Response Relationsh | 2003 |
New agents in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Anti | 1984 |
18 trials available for mitoxantrone and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Pr | 2012 |
New agents in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Anti | 1984 |
An intensive treatment with mitoxantrone and ifosfamide in second-line therapy of epithelial ovarian cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Administration Schedule; Fema | 1994 |
Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1994 |
[Comparison of the therapeutic effect of CMxMF and CAMF regimens in the management of advanced breast cancer patients].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brea | 1993 |
A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver.
Topics: Adult; Aged; Carcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Female; Hepatic Artery; Hum | 1993 |
Multicenter phase II trial of mitoxantrone in patients with advanced nasopharyngeal carcinoma in Southeast Asia: an Asian-Oceanian Clinical Oncology Association Group study.
Topics: Adult; Aged; Carcinoma; Female; Hematologic Diseases; Humans; Male; Middle Aged; Mitoxantrone; Nasop | 1993 |
Ifosfamide and mitoxantrone as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Drug Admin | 1993 |
Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 1997 |
A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Carbo | 1997 |
Intraperitoneal cisplatin-mitoxantrone and intravenous ifosfamide combination as first-line treatment of ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Feasibility Studi | 1998 |
Concomitant chemoradiotherapy for patients with nonmetastatic breast carcinoma: side effects, quality of life, and organization.
Topics: Activities of Daily Living; Adult; Antineoplastic Combined Chemotherapy Protocols; Appetite; Breast | 1999 |
Peritoneal carcinomatosis from ovarian cancer: cytoreductive surgery and intraperitoneal chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Female | 1999 |
Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosp | 1999 |
Duration of chemotherapy in advanced breast carcinoma.
Topics: Breast Neoplasms; Carcinoma; Drug Administration Schedule; Female; Humans; Mitoxantrone; Randomized | 1990 |
Combination therapy for anaplastic giant cell thyroid carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 1991 |
Intraperitoneal mitoxantrone as consolidation treatment for stage III ovarian carcinoma: a pilot study.
Topics: Adult; Aged; Carcinoma; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Middle Aged; | 1991 |
A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials | 1988 |
34 other studies available for mitoxantrone and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Treatment of genitourinary carcinoma in dogs using nonsteroidal anti-inflammatory drugs, mitoxantrone, and radiation therapy: A retrospective study.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma; Dog Diseases; | 2021 |
Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin | 2014 |
Nonfunctioning Adrenocortical Carcinoma in Pediatric Acute Lymphoblastic Leukemia: A Case Report of a Rare Multiple Primaries Combination.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; | 2017 |
[Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autografts; Brea | 2017 |
Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clinical Protocols; Dise | 2011 |
Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.
Topics: Adult; Antineoplastic Agents; Carcinoma; Cohort Studies; Colonic Neoplasms; Demyelinating Diseases; | 2003 |
Secondary leukaemia after MMM combined modality therapy for breast carcinoma.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; F | 1993 |
Liposomal mitoxantrone for the local treatment of peritoneal carcinomatosis induced by colon cancer cells in mice.
Topics: Animals; Carcinoma; Colonic Neoplasms; Drug Carriers; Electrochemistry; Female; Liposomes; Male; Mic | 1994 |
Mitoxantrone in the treatment of recurrent ascites of pretreated ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma; Chromatography, Hig | 1994 |
Primary chemotherapy and radiosurgical breast-conserving treatment for patients with locally advanced operable breast cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Intraductal, | 1993 |
Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy.
Topics: Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Female; Follow-Up Studies; Humans; Infusions, Parenter | 1993 |
Factors affecting acute skin toxicity in patients having breast irradiation after conservative surgery: a prospective study of treatment practice at the Royal Marsden Hospital.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carc | 1996 |
Salvage intraperitoneal therapy of advanced epithelial ovarian cancer: impact of retroperitoneal nodal disease.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 1997 |
[The lymphotropic marking and biopsy of sentinel lymph nodes in T1 tumors--a new approach to the staging of axillary lymphatic metastasis in breast cancer].
Topics: Anthraquinones; Antineoplastic Agents; Axilla; Biopsy; Breast Neoplasms; Carcinoma; Coloring Agents; | 1997 |
Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Transport | 1998 |
Theoretical considerations and in vitro concentration response studies with two human colorectal carcinoma cell lines. The rational experimental base for clinical studies in regional chemotherapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2000 |
Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Biopsy, Needle; Breast | 2000 |
Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Topics: Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding | 2001 |
Intraperitoneal mitoxantrone: a feasibility and pharmacokinetic study.
Topics: Adult; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Sched | 2002 |
Hyperthermia enhances mitoxantrone cytotoxicity on human breast carcinoma and sarcoma xenografts in nude mice.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Drug Resistance; Female; Humans; Hypert | 1992 |
Aplastic anemia in a patient receiving tamoxifen.
Topics: Anemia, Aplastic; Breast Neoplasms; Carcinoma; Female; Humans; Middle Aged; Mitoxantrone; Tamoxifen | 1991 |
Intensive chemotherapy with cisplatin, mitoxantrone, methotrexate and vincristine in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Femal | 1991 |
Efficacy of mitoxantrone against various neoplasms in dogs.
Topics: Animals; Carcinoma; Dog Diseases; Dogs; Lymphoma; Mitoxantrone; Neoplasms; Prospective Studies; Remi | 1991 |
[Chemotherapy of highly malignant thyroid tumors].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Small Cell; Cisplatin; C | 1990 |
[Clinical and histological study on breast cancer treated by preoperative mitoxantrone].
Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Female; Humans; Middle Aged; Mi | 1990 |
Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer.
Topics: Carcinoma; Drug Evaluation; Female; Humans; Infusions, Parenteral; Mitoxantrone; Ovarian Neoplasms; | 1990 |
Biological evaluation of mitoxantrone dihydrochloride synthesized by a new method. I. Acute toxicity and antitumor activity in mouse transplantable tumor systems.
Topics: Animals; Antineoplastic Agents; Carcinoma; Dose-Response Relationship, Drug; Female; Lethal Dose 50; | 1989 |
Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Carcinoma; Chromosome | 1988 |
Effectiveness of mitoxantrone on the proliferation of cell cultures derived from malignant mesenchymal tumors of human origin.
Topics: Adolescent; Adult; Aged; Carcinoma; Cell Division; Cisplatin; DNA; Doxorubicin; Humans; Middle Aged; | 1988 |
[Arterial regional chemotherapy of advanced breast cancer].
Topics: Breast Neoplasms; Carcinoma; Combined Modality Therapy; Drug Evaluation; Female; Humans; Infusions, | 1988 |
Development of resistance and characteristics of a human colon carcinoma subline resistant to mitoxantrone in vitro.
Topics: 2,4-Dinitrophenol; Carcinoma; Cell Nucleus; Colonic Neoplasms; Dinitrophenols; DNA, Neoplasm; Drug R | 1987 |
Effect of hyperthermia on the sensitivity of human colon carcinoma cells to mitoxantrone.
Topics: Carcinoma; Colonic Neoplasms; Humans; Hyperthermia, Induced; In Vitro Techniques; Mitoxantrone | 1987 |
Mitoxantrone in the treatment of advanced non-squamous carcinoma of the cervix (a phase II trial of the gynecologic oncology group).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma; Drug Evaluation; Female; Humans; Middle A | 1987 |
Growth and characterization of multicellular tumor spheroids of human bladder carcinoma origin.
Topics: Anthraquinones; Carcinoma; Cell Division; Cell Line; Humans; Mitoxantrone; Urinary Bladder Neoplasms | 1986 |